SNTI vs. CTMX, ZIVO, ONCY, VHAQ, ANVS, SLS, BYSI, RVPH, MURA, and IMRX
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include CytomX Therapeutics (CTMX), ZIVO Bioscience (ZIVO), Oncolytics Biotech (ONCY), Viveon Health Acquisition (VHAQ), Annovis Bio (ANVS), SELLAS Life Sciences Group (SLS), BeyondSpring (BYSI), Reviva Pharmaceuticals (RVPH), Mural Oncology (MURA), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.
Senti Biosciences vs.
CytomX Therapeutics (NASDAQ:CTMX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
CytomX Therapeutics received 368 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 65.38% of users gave CytomX Therapeutics an outperform vote while only 40.00% of users gave Senti Biosciences an outperform vote.
CytomX Therapeutics has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Comparatively, 15.9% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
CytomX Therapeutics has a net margin of 10.96% compared to Senti Biosciences' net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat Senti Biosciences' return on equity.
CytomX Therapeutics currently has a consensus price target of $5.77, indicating a potential upside of 562.59%. Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 123.71%. Given CytomX Therapeutics' higher probable upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Senti Biosciences.
CytomX Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.
In the previous week, CytomX Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Senti Biosciences. CytomX Therapeutics' average media sentiment score of 0.93 beat Senti Biosciences' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.
Summary
CytomX Therapeutics beats Senti Biosciences on 14 of the 18 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senti Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:SNTI) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SNTI Stock Alerts